Table 2.
Current and expected PCV coverage of pneumococcal serotypes from nasopharynx swab (n=75) and pneumococcal disease (n=113) isolates, Pakistan, 2006–2020; data are n (%)
|
Vaccine |
Nasopharyngeal isolates (n=75) |
Disease-causing isolates (n=113) |
Disease-causing isolates from children ≤5 years (n=42) |
|---|---|---|---|
|
PCV10 |
17 (22.7 %) |
40 (35.4 %) |
16 (38.1 %) |
|
PCV13 |
26 (34.7 %) |
55 (48.7 %) |
23 (54.8 %) |
|
PCV15* |
26 (34.7 %) |
56 (49.6 %) |
23 (54.8 %) |
|
PCV20† |
40 (53.3 %) |
72 (63.7 %) |
27 (64.3 %) |
|
PCV24‡ |
40 (53.3 %) |
78 (69 %) |
28 (66.7 %) |
|
PCV25/IVT-25§ |
41 (54.7 %) |
73 (64.6 %) |
114 (60.6 %) |
|
Pneumosil¶ |
19 (25.3) |
43 (38.1 %) |
20 (69 %) |
*PCV15 is under review for use in individuals >18 years old.
†PCV20 is approved by the FDA for use in individuals >18 years old.
‡PCV24 is under development.
§VT-25 is a PCV25 that covers against serotypes responsible for causing invasive infections in children in low- and middle-income countries. As PCV25 contains 24F, serogroup 24 was included in PCV25 types.
¶Pneumosil is a PCV10 that covers against serotypes 6A and 19A.